Isoform-Specific Loss Of Dystonin Causes Charcot-Marie-Tooth Disease
By LabMedica International staff writers Posted on 20 Aug 2020 |
The HiSeq 2000 Sequencing System (Photo courtesy of Illumina).
Charcot-Marie-Tooth (CMT) disease, also called hereditary motor and sensory neuropathy, is among the most common neurogenetic diseases and is characterized by progressive length-dependent weakness and sensory loss.
CMT is divided into demyelinating (type 1) and axonal (type 2) forms of the disease based on clinical, electrophysiological, histological, and genetic features. Recessively inherited demyelinating neuropathies are called CMT4, whereas recessively inherited axonal neuropathies are called autosomal recessive (AR)-CMT.
Neurologists at the University of Pennsylvania School of Medicine (Philadelphia, PA, USA) and their colleagues applied whole exome sequencing (WES) to analyze the more than 30 million base pairs of DNA that encode the 20,000 proteins in humans. By examining three siblings, two affected and one unaffected, they were able to deduce the genetic basis of mutations that caused the two siblings to be affected.
Genomic DNA was isolated from peripheral blood from all participants. Exome DNA was captured using the SureSelect, Human All Exon5 50 Mb kit (Agilent Technologies, Santa Clara, CA, USA) and sequenced on a HiSeq 2000 (Illumina, San Diego, CA, USA). RNA was isolated from skin using the ZR-Duet DNA/RNA MiniPrep Plus kit (Zymo, Irvine, CA, USA). Complementary DNA (cDNA) was reverse transcribed using SuperScript III First-Strand Synthesis System (Invitrogen, Waltham, MA, USA).
The team identified compound heterozygous mutations in dystonin (DST), which is alternatively spliced to create many plakin family linker proteins (named the bullous pemphigoid antigen 1 [BPAG1] proteins) that function to bridge cytoskeletal filament networks. One mutation (c.250C>T) is predicted to cause a nonsense mutation (p.R84X) that only affects isoform 2 variants, which have an N-terminal transmembrane domain; the other (c.8283+1G>A) mutates a consensus splice donor site and results in a 22 amino acid in-frame deletion in the spectrin repeat domain of all BPAG1a and BPAG1b isoforms.
Steven S. Scherer, MD, PhD, a professor of Neurology and senior author of the study, said, “We are in the era where treatments for genetic diseases are possible. This brother and sister stand to benefit from that approach because we know the gene that is missing, and if we could replace it, that should at least prevent their progression.”
The authors concluded that their findings introduce a novel human phenotype, axonal Charcot-Marie-Tooth, of recessive DST mutations, and provide further evidence that BPAG1 plays an essential role in axonal health. The study was published on July 31, 2020 in the journal Neurology Genetics.
Related Links:
University of Pennsylvania School of Medicine
Agilent Technologies
Illumina
Zymo
Invitrogen - Thermo Fisher
CMT is divided into demyelinating (type 1) and axonal (type 2) forms of the disease based on clinical, electrophysiological, histological, and genetic features. Recessively inherited demyelinating neuropathies are called CMT4, whereas recessively inherited axonal neuropathies are called autosomal recessive (AR)-CMT.
Neurologists at the University of Pennsylvania School of Medicine (Philadelphia, PA, USA) and their colleagues applied whole exome sequencing (WES) to analyze the more than 30 million base pairs of DNA that encode the 20,000 proteins in humans. By examining three siblings, two affected and one unaffected, they were able to deduce the genetic basis of mutations that caused the two siblings to be affected.
Genomic DNA was isolated from peripheral blood from all participants. Exome DNA was captured using the SureSelect, Human All Exon5 50 Mb kit (Agilent Technologies, Santa Clara, CA, USA) and sequenced on a HiSeq 2000 (Illumina, San Diego, CA, USA). RNA was isolated from skin using the ZR-Duet DNA/RNA MiniPrep Plus kit (Zymo, Irvine, CA, USA). Complementary DNA (cDNA) was reverse transcribed using SuperScript III First-Strand Synthesis System (Invitrogen, Waltham, MA, USA).
The team identified compound heterozygous mutations in dystonin (DST), which is alternatively spliced to create many plakin family linker proteins (named the bullous pemphigoid antigen 1 [BPAG1] proteins) that function to bridge cytoskeletal filament networks. One mutation (c.250C>T) is predicted to cause a nonsense mutation (p.R84X) that only affects isoform 2 variants, which have an N-terminal transmembrane domain; the other (c.8283+1G>A) mutates a consensus splice donor site and results in a 22 amino acid in-frame deletion in the spectrin repeat domain of all BPAG1a and BPAG1b isoforms.
Steven S. Scherer, MD, PhD, a professor of Neurology and senior author of the study, said, “We are in the era where treatments for genetic diseases are possible. This brother and sister stand to benefit from that approach because we know the gene that is missing, and if we could replace it, that should at least prevent their progression.”
The authors concluded that their findings introduce a novel human phenotype, axonal Charcot-Marie-Tooth, of recessive DST mutations, and provide further evidence that BPAG1 plays an essential role in axonal health. The study was published on July 31, 2020 in the journal Neurology Genetics.
Related Links:
University of Pennsylvania School of Medicine
Agilent Technologies
Illumina
Zymo
Invitrogen - Thermo Fisher
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans